Background -Canine atopic dermatitis (cAD) is associated with an imbalance between multiple T lymphocytes and cytokines. Ex vivo boosted immune cell (EBIC) therapy is the sequential administration of ex vivo cultured and activated lymphocytes to patients to improve immune function.
Introduction
Canine atopic dermatitis (cAD) is a common chronic inflammatory skin disorder resulting from genetic and environmental factors. Although the pathogenesis of atopic dermatitis (AD) in dogs is not fully understood, recent studies suggest that AD is associated with an imbalance between a variety of T-cell phenotypes and cytokines. 1 In humans and dogs with AD, the number of circulating CD4 + T cells is significantly increased compared to that in healthy controls, resulting in an increased CD4 + /CD8 + ratio. 2 Additionally, through several mechanisms, IFN-c reduces skin inflammation and is considered to be a key cytokine in human and canine AD. [3] [4] [5] In humans, ex vivo boosted immune cell (EBIC) therapy immune cells are isolated from the patient's peripheral blood mononuclear cells (PBMCs), expanded ex vivo and then infused back into the same patient. This therapy is similar to the transfusion of lymphokine-activated killer T (T-LAK) cells in humans which involves the administration of autologous lymphocytes that have been proliferated by stimulation and culture with certain cytokines. 6 Through this therapy, human patients and dogs receive a number of activated immune cells to improve immune function. [6] [7] [8] Ex vivo cell transfer can be used to treat a variety of pathological conditions, particularly cancer. [9] [10] [11] This treatment has not been applied to skin diseases in animals or humans.
In ex vivo culture, the characteristics of EBICs are comparable to those of PBMCs in that (1) the CD8 + T cells increase in proportion and predominate, and (2) the proportion of IFN-c-producing cells increases significantly. Transfusion of activated canine lymphocytes has been reported to reinforce the recipient's immune response and increases the recipient's serum interferongamma (IFN-c) concentration. 8, 12 IFN-c, interleukin (IL)-4, IL-10 and IL-31 have been reported to play important roles in dogs with AD. 13 Identifying trends in the levels of these cytokines may be helpful for understanding the efficacy of EBIC and changes in immune cells in dogs with cAD.
We hypothesized that EBIC therapy could correct the immunological imbalance in dogs with cAD and improve the clinical signs associated with it. Therefore, the aim of this study was to evaluate the efficacy of EBIC therapy as a novel treatment for cAD and to assess its safety.
Methods and materials Dogs
The study was conducted in compliance with the guidelines of the Institutional Animal Care and Use Committee. All owners were required to sign an informed consent form for the clinical trials before enrolling their animals in the study.
Atopic dogs of any breed or sex were included, based on published criteria.
14,15 Dogs with other pruritic skin diseases were excluded using standard methods including Wood's lamp, skin scraping and impression smear cytological evaluation. Because repeated collection of approximately 15 mL of blood (10 mL for cell culture and 5 mL for laboratory tests) was required, dogs <6 months of age and/or those weighing <3 kg were excluded from the study. Dogs were not included if they had been treated with oral corticosteroids within the previous four weeks, long-acting injectable corticosteroids within the previous eight weeks, or ciclosporin within the previous eight weeks. Lactating or pregnant dogs, or those presenting with a zoonosis also were excluded. Before the study, ectoparasite infestation was ruled out for all dogs, and products were used throughout the trial with topical spoton anti-ectoparasiticides. If secondary infections (superficial pyoderma, Malassezia dermatitis or otitis externa) were identified during the study through cytological evaluation, the dogs were treated with oral and topical antimicrobial drugs, as required. The use of any form of glucocorticoid or immunoregulatory treatment was prohibited during the clinical trial except in the case of emergencies such as anaphylactic shock. Throughout the study period, dogs were kept in their usual environment including their usual diet.
EBIC culture
The isolation, culture and expansion of immune cells were performed with modifications according to procedures reported in previous studies. 8, 12 Two weeks before starting EBIC therapy, 10 mL of the dog's own peripheral blood was collected in vacuum tubes coated with heparin (BD Vacutainer â , Becton Dickinson; Franklin Lakes, NJ, USA). Each blood sample was transferred to a 15-mL conical tube and centrifuged at 800 g for 10 min to separate it into plasma and blood cells.
In order to isolate lymphocytes, the blood cells were diluted with equal volumes of RPMI 1640 medium (HyClone Laboratories, Inc.; Logan, UT, USA) and layered carefully over Ficoll-Paque â PLUS (density 1.077; GE Healthcare Bio-Science; Uppsala, Sweden). The samples were then centrifuged at 400 g for 30 min. The mononuclear cell layer was then transferred to a clean 15 mL conical tube. To remove the red blood cells, 0.83% ammonium chloride was added to the conical tube and the tube was rinsed twice with 19 phosphatebuffered saline (PBS, Welgene Inc.; Daegu, Korea). After washing, the cells were suspended in RPMI 1640 medium and counted. The day before cell culture, PBMCs (1 9 10 7 cells) were obtained in a flask coated with anti-canine CD3 antibodies and incubated at 37°C in a humidified atmosphere with 5% CO 2 in 5 mL RPMI-1640 culture medium supplemented with 10% fetal bovine serum (Gibco Laboratories; Gaithersburg, MD, USA), 2 mM L-glutamic acid (Gibco Laboratories), 19 antibiotic-antimycotic (Gibco Laboratories) and human recombinant IL-2 (Proleukin â , Novartis Pharmaceuticals; Basel, Switzerland). The final concentration of IL-2 was 1,000 IU/mL. 16 EBICs were cultured for 13 days; during cell culture, the culture medium was replaced by fresh medium containing IL-2 every 2-3 day.
Characteristics of PBMCs and activated lymphocytes
We analysed the phenotypes of immune cells pre-and post-culture by flow cytometry. ) were suspended in 100 lL of fluorescence-activated cell sorting (FACS) staining buffer (eBioscience; San Diego, CA, USA) and then transferred to a 5 mL sample tube. For phenotypic analyses, cells were stained according to the manufacturer's instructions with the following volumes or amounts of antibodies: 3 lL of anti-canine CD3 fluorescein isothiocyanate (FITC, AbD Serotec; Oxford, UK), 1 lL of anti-canine CD21 RPE (AbD Serotec), 1 lL of anti-canine CD45 APC (AbD Serotec), 3 lL of anti-canine CD5 RPE (AbD Serotec), 2.5 lL anti-canine CD4 PE-Cyanine7 (eBioscience), 2 lL of anticanine CD8a PerCP-eFluor710 (eBioscience), 2.5 lL of anti-canine CD25 FITC (eBioscience) and 0.5 lg of anti-mouse/rat FoxP3 APC (eBioscience). Isotype-matched antibodies were used as controls for nonspecific binding. Staining was performed at 4°C in the dark for 30 min. After washing the cells twice with 19 PBS, 4% paraformaldehyde was added for fixation. Fixed cells were analysed using a Gallios flow cytometer (Beckman Coulter; Brea, CA, USA) and KALUZA software (Beckman Coulter).
Proportion of IFN-c-producing cells
Changes in the proportions of IFN-c-producing cells pre-and post-cell culture were examined. For activation, 0.5 mL of each blood sample was added to 0.5 mL RPMI 1640 medium and incubated for 4 h with 40 ng/mL PMA (phorbol 12-myristate 13-acetate â , Sigma-Aldrich; St Louis, MO, USA) and 1 lg/mL Brefeldin A (Sigma-Aldrich). 17 EBICs prepared at 5 9 10 6 cells/mL were added to RPMI 1640 medium and stimulated with 40 ng/mL PMA, 1 lg/mL ionomycin (Sigma-Aldrich) and 5 lg/mL brefeldin A. The cells were incubated for 4 h at 37°C. Nine millilitres of 0.83% ammonium chloride was then added to remove red blood cells. After washing, the cells were suspended in FACS staining buffer and stained with monoclonal antibodies in the dark for 30 min. The antibodies used were anti-canine CD3 FITC, anti-canine CD8a PerCP-eFluor710, anti-canine CD4 PE-Cyanine7 and anti-canine CD45 allophycocyanin. All antibodies were purchased from AbD Serotec. Samples were rinsed with PBS and fixed with 100 lL IC buffer (eBioscience) for 60 min. After fixation, cells were washed with 300 lL 19 permeabilization buffer (eBioscience). The washed cells were suspended in permeabilization buffer and stained with antibovine IFN-c (AbD Serotec) in the dark for 30 min. Isotype-matched antibodies were used as controls. The samples were then rinsed with permeabilization buffer and resuspended in 300 lL of FACS staining buffer.
Clinical assessments
In order to evaluate the extent and severity of skin lesions, clinical trials included dogs with cAD, based on the investigator's assessment using Canine Atopic Dermatitis Extent and Severity Index, 3 rd iteration (CADESI-03) score. 18, 19 Dogs were classified according to their CADESI scores as severe (score > 120), moderate (60 < score ≤ 119), mild (16 < score ≤ 59) or insignificant (score ≤ 15). The same investigator scored the animals on each evaluation day. Pruritus was evaluated based on the owners' observations. The severity of pruritus was scored as none (0), mild (1), moderate (2-3) or severe (4-5).
Owners observed manifestations related to pruritus and provided the score to veterinarians at each appointment. There were no minimal or maximal CADESI or pruritus scores to define inclusion/exclusion criteria. Information regarding adverse events was recorded by the attending veterinarian.
Laboratory evaluation
On each injection day, approximately 5 mL of blood was obtained by jugular venipuncture and collected in EDTA and heparin tubes for complete blood counts (CBC) and serum chemistry panels. Additionally, to quantify IFN-c, IL-4, IL-10 and IL-31 in the dog's blood, enzyme-linked immunosorbent assay (ELISA) was performed according to the manufacturer's instructions. The ELISA kits used were the Canine IFN-c ELISA kit (Kit no. MBS021339, detection range 6.25-200 pg/mL, MyBioSource; San Diego, CA, USA), Canine IL-4 ELISA kit (Kit no. MBS042172, detection range 6.25-200 pg/mL, MyBioSource), Canine IL-10 ELISA kit (Kit no. MBS038615, detection range 6.25-200 pg/mL, MyBioSource) and Canine IL-31 ELISA kit (Kit no. MBS025098, detection range 3.12-100 pg/mL, MyBioSource).
Study design
The owners and dogs visited the hospital once every two weeks for EBIC therapy. After each visit, owners were interviewed by a veterinarian to check the dog's health and record pruritus scores. After each owner interview, the veterinarian performed a physical examination and assigned a CADESI-03 score. Prior to each infusion, 15 mL of peripheral blood was obtained by jugular venipuncture; 10 mL samples were used for culture and expansion of cells for the next infusion, and 5 mL was used for routine laboratory evaluations. All dogs received intravenous (i.v.) infusions of EBICs suspended in 10-20 mL of normal saline every two weeks for a total of six injections. The starting infusion rate was low (0.5 mL/kg/h). The infusion rate was then increased gradually up to a maximum infusion rate of 20 mL/kg/h. In the event that an adverse event was to occur, including hypersensitivity reaction or vomiting, the infusion was to be stopped and dexamethasone or antihistamine drugs were to be administered at the discretion of the veterinarian.
In order to evaluate the post-treatment efficacy of EBIC therapy, dogs were followed up by telephone calls to their owners or during hospital visits at least once per week for eight weeks after treatment. Eight weeks after the last infusion, all dogs returned to the clinic and underwent the tests described above. The overall study timeline is shown in Figure 1 .
Statistical analysis
Statistical analyses were performed using commercially available software (SigmaPlot â 12.0, Systat Software Inc.; San Jose, CA, USA). All data were expressed as mean AE standard error of the mean. PBMCs (before culture) and EBICs (13 days after culture) were compared using a paired Student's t-test. The Shapiro-Wilk test was used to test for normality. To determine the statistical significance of the clinical results, changes in CADESI and pruritus scores were analysed using one way repeated measures ANOVA followed by Dunnett's multiple comparison test. A P-value ≤0.05 was considered significant.
Results

Subjects
Ten dogs with cAD were enrolled. These included three shih tzus, two French bulldogs, one Yorkshire terrier, and one each of dachshund, Maltese terrier, bull terrier and spitz. The age of the dogs at admission ranged from 1-year-old to 13-year-old (mean 6.6-year-old). Table 1 shows other characteristics recorded at baseline and the mean counts of cells administered by i.v. injection.
Characteristics of immune cells
The PBMCs from the 10 dogs were isolated and cultured six times for 13 days each, producing a total of 60 samples that were expanded ex vivo. The cells were expanded 52.57 AE 6.30-fold compared to the initial samples. Changes were observed in the proportion of PBMCs and EBICs, as shown in Figure 2 . After cell expansion, the percentage of T cells increased from 77.16 AE 1.17% to 97.53 AE 0.46% (P < 0.001). The proportion of cytotoxic T cells among the total T cells was significantly increased (27.03 AE 1.02% to 69.43 AE 3.12%, P < 0.001), whereas the proportion of helper T cells was significantly decreased (55.36 AE 1.47% to 3.26 AE 1.26%, P < 0.001). The number of B cells decreased from 13.03 AE 0.96% to 0.18 AE 0.03% (P < 0.001 for both). The number of Treg cells also decreased significantly from 4.64 AE 0.13 to 0.13 AE 0.09 (P < 0.001). 
Proportion of IFN-c-producing cells
We also identified changes in the proportions of IFNc-producing cells. Following ex vivo cell culture, the proportions of IFN-c-producing cells increased from 14.34 AE 1.15% to 65.75 AE 1.62% (P < 0.001, Figure 1 ). Additionally, among PBMCs, the proportion of CD4 + / IFN-c + or CD8 + /IFN-c + double positive (DP) cells was observed serially. Figure 3 shows the changes in proportion of interferon gamma producing T cell (Figure 3a , for the CD4, Figure 3b : for the CD8) among total PBMCs during sequential therapy. During therapy, the number of CD8 + /IFN-c + DP cells increased gradually, whereas CD4 + /IFN-c + DP cell numbers showed no meaningful changes.
Clinical assessments
Changes in CADESI scores throughout the study are shown in Figure 4 . No dogs were categorized as having insignificant disease, four dogs were categorized as mild, three dogs were categorized as moderate and three dogs were categorized as severe. For convenience, the mild and moderate groups were combined into a mild/ moderate group for statistical evaluation. Prior to the administration of EBIC therapy, mean CADESI scores were 101 AE 24.70 for all dog groups, 191 AE 56.10 for the severe group and 63.00 AE 5.85 for the mild/moderate group. Eight weeks after the completion of therapy, the mean score was decreased significantly to 39.10 AE 12.84 for all dogs (P < 0.001). The mean scores for the severe and mild/moderate groups were 82.33 AE 30.93 (reduced by 57.57 AE 15.05%, P = 0.017) and 20.57 AE 5.08 (reduced by 69.24 AE 6.21%, P < 0.001), respectively.
Changes in pruritus scores are shown in Figure 5 . Before treatment, the pruritus scores ranged from 2 to 5; the mean scores were 3.50 AE 0.27, 4.00 AE 0.58 and 3.29 AE 0.29 for all dogs, the severe group and the mild/moderate group, respectively. Compared with pretreatment, the pruritus scores decreased significantly by two weeks after the fifth injection and the follow-up day (both P < 0.001). By the last follow-up day, the pruritus scores were reduced by 58.87 AE 4.84% (from 4.00 AE 0.58 to 1.67 AE 0.33, P = 0.016) and 52.38 AE 16.93% (from 3.29 AE 0.29 to 1.57 AE 0.57, P < 0.001), when compared to pretreatment scores in the severe and mild/moderate groups, respectively.
Laboratory evaluations and adverse events
There were no significant differences in CBCs or serum chemistry before and after treatment. Serum cytokines were detected in all dogs at each evaluation time (Figure 6) . IFN-c, IL-4 and IL-10 also were detected in all subjects at each evaluation time, whereas IL-31 was detected in seven of the 10 dogs. In three dogs, the serum IL-31 level was <3.12 ng/mL. There were no statistically significant differences between cytokine concentrations at any evaluation point.
All dogs were evaluated for adverse events throughout the study and no significant severe adverse effects, such as anaphylactic shock, were observed. Facial angioedema occurred once in one dog during the study. From the next therapy, this dog was treated with dexamethasone Enrolled dogs received EBICs every other week. CADESI-03 scores were assessed every other week before administration of EBICs (total: n = 10; severe: n = 3; mild/ moderate: n = 7). CADESI-03 scores of total (a), severe (b) and mild/moderate (c) groups. The data are expressed as the mean AE standard error of the mean (*P < 0.05 compared with pretreatment, **P < 0.01 compared with pretreatment); first, two weeks after first injection; F/U, follow-up day. Figure 5 . Changes in pruritus scores after administration of ex vivo boosted immune cells (EBICs). Dogs were administered EBICs every other week. Pruritus scores were assessed every other week before administration of EBICs (total: n = 10; severe: n = 3; mild/moderate: n = 7). Pruritus scores of total (a), severe (b) and mild/moderate (c) groups. Data are expressed as mean AE standard error of the mean (*P < 0.05 compared with pretreatment, **P < 0.01 compared with pretreatment); first, two weeks after first injection; F/U, follow-up day. (0.5 mg/kg) before injection at each subsequent visit and angioedema was not observed again.
Discussion
This study has shown that application of EBIC injections, repeated every two weeks over a total of six injections, is an effective treatment for cAD in the population studied. EBIC therapy was effective in alleviating pruritus and this effect was maintained after the injections were finished. In addition, the effect was similar in both the severe and mild/moderately affected groups. CADESI scores dropped significantly compared to baseline values, and eight weeks after stopping therapy the scores were still significantly decreased. The overall efficacy of EBIC therapy based on the severity of skin lesions was greater for the mild/moderately affected group than the severely affected group. We cannot explain the specific mechanism of action of EBIC therapy, yet our results suggest that IFN-c may play a central role in the positive effects of EBIC therapy in dogs with cAD. Following ex vivo cell culture the proportions of IFN-c-producing cells increased significantly. An imbalance between Th1 and Th2 is a primary characteristic of human AD and studies have shown that IFN-c inhibits the growth of Th2 cells and promotes TH1 development. [3] [4] [5] 20 In a previous study, serum IFN-c concentration in healthy dogs increased gradually after sequential administration of activated lymphocytes. Recombinant canine IFN-c therapy also has been shown to produce notable clinical improvement of cAD cases. 21 Unfortunately, no changes in the serum IFN-c concentration of dogs were found throughout the present study. We speculate that this discrepancy might have been caused by differences in the health status of the dogs. In a previous study, the subjects were healthy dogs with no skin problems, whereas the dogs in our study had AD. We analysed only 10 dogs in the present study. Thus, additional studies are needed to confirm our hypothesis and determine the exact mechanisms of EBICs.
We determined the serum levels of other cytokines (IL-4, IL-10 and IL-31). In previous studies about the PBMCs from dogs with cAD, the levels of IL-4 and IL-10 were higher than those from normal controls, whereas that of IFN-c was lower; however, the normal levels of these cytokines were not always restored after treatment was applied. [22] [23] [24] Similar to the results of previous studies, we found no immunological effects of EBICs on serum IL-4, IL-10 and IFN-c levels. In a previous study, serum IL-31 was reported in 57% of dogs with AD; it was not detected in dogs with pruritic skin disease, fleaallergic dogs or dogs sensitized to house dust mite allergens. 25 In our study, serum IL-31 was detected in seven of the 10 dogs; this trend was similar to that reported by the previous study. There were no changes in IL-31 levels during EBIC therapy, although pruritus was alleviated over the course of the study.
In the present study, a 52.57-fold increase in the number of PBMCs was found after culture. A different proliferative ability was established in each of the dogs studied and because of this, there was a difference between individual subjects in the number of cells injected. However, there was no significant difference between injected cell numbers and efficacy. CD8+ cells were predominant among the activated lymphocytes, and a significantly increased number of IFN-c-producing cells were observed. These results are consistent with those obtained in previous studies. 8, 12 We assessed changes in circulatory Treg cells. Less is known about the behaviour of Tregs in the pathogenesis of cAD and previous studies have shown that the number of Tregs in circulation is increased in dogs with cAD compared to healthy dogs. [26] [27] [28] The proportions of Treg cells in our study were similar to those in a previous study. [26] [27] [28] Throughout our study, the mean percentage of Tregs in circulation was 4.64 AE 0.13 and there was no significant difference in Treg percentage over time. However, there was a significant difference in the Treg percentages between the severely affected group and mild/moderately affected group. At the beginning of the study, the mean Treg percentage was 7.13% and 3.07% in these groups, respectively. Studies in humans have shown that patients with AD have significantly increased numbers of peripheral blood Treg cells and that the increase in the percentage of Tregs is positively correlated with patients' clinical scores. 29, 30 However, according to previous studies, changes in the Treg cell proportions after treatment of human AD vary greatly. 31, 32 Less is known about the Treg response to therapy in dogs with cAD. One study reported that the number of circulating Tregs was increased following allergen-specific immunotherapy. 33 Another study reported that ciclosporin therapy in dogs with cAD did not affect circulating Treg cells populations. 26 No significant adverse events were observed during this study, and no significant differences were detected in body weight, CBC, blood chemistry or eating habits. These results suggest that EBIC is a safe therapy for cAD treatment, but larger numbers of treated dogs will be necessary to reveal uncommon or rare adverse events. In addition, the clinical signs of cAD often wax and wane over time, so larger numbers of subjects will be needed to generalize their results to other canine populations. Ultimately, appropriately powered randomized and controlled studies will be necessary to validate the safety and efficacy of EBIC therapy.
Conclusions et importance clinique -Le traitement EBIC est sûr et efficace pour la cAD. Ce traitement pourrait corriger le d es equilibre immunologique des chiens avec AD par l'administration de lymphocytes T activ es.
Resumen
Introducci on -la dermatitis at opica canina (cAD) se asocia con un desequilibrio entre m ultiples poblaciones de linfocitos T y citoquinas. El tratamiento con c elulas inmunes potenciadas ex vivo (EBIC) es la administraci on secuencial de linfocitos cultivados y activados ex vivo a pacientes para mejorar la funci on inmunitaria. Objetivo -Este estudio piloto tuvo como objetivo evaluar la seguridad del tratamiento con EBIC y demostrar su eficacia como un nuevo tratamiento para la cAD. Animales -Diez perros con AD. M etodos y materiales -Los fenotipos de las c elulas inmunes antes y despu es del cultivo ex vivo se analizaron mediante citometr ıa de flujo. Los EBIC (1,0-5,0 9 10 8 c elulas/animal) se administraron a perros cada dos semanas, con un total de seis inyecciones. Se calcularon los ındices de extensi on y severidad de la cAD (CADESI)-03 y el prurito para evaluar la eficacia del tratamiento con EBIC para la cAD. Para la evaluaci on de la seguridad del tratamiento, se realizaron an alisis de sangre regulares y se registraron los efectos adversos. Se evaluaron los niveles s ericos de interleuquina (IL)-4, IL-10, IL-31 e interfer on-gamma (IFNc).
Resultados -Las c elulas se expandieron en un promedio de 57,52 veces y las proporciones de c elulas CD8 + y c elulas productoras de IFN-c aumentaron significativamente despu es del cultivo ex vivo. La terapia EBIC secuencial mejor o CADESI-03 y las puntuaciones de prurito de manera significativa. Despu es de suspender el tratamiento, las tasas de mejor ıa aumentaron para el valor de CADESI y se mantuvieron para el valor del prurito. No hubo cambios significativos en los niveles de citoquinas. No se observaron eventos adversos significativos. Conclusiones y significado cl ınico -la terapia EBIC es un tratamiento seguro y eficiente para la cAD. Esta terapia podr ıa corregir el desequilibrio inmunol ogico en perros con AD mediante la infusi on de linfocitos T activados. Ergebnisse -Die Zellen nahmen durchschnittlich um das 57,52 fache und die Proportion der CD8 + Zellen und der IFN-c produzierenden Zellen nahm nach der ex vivo Kultur signifikant zu. Die fortlaufende EBIC Therapie verbesserte den CADESI-03 sowie die Juckreizwerte signifikant. Nach Ende der Behandlung nahmen die Verbesserungsraten f€ ur den CADESI Score zu und blieben bei den Juckreizwerten konstant. Es gab keine signifikanten Ver€ anderungen bei den Zytokinwerten. Es wurden keine signifikanten Nebenwirkungen beobachtet. Schlussfolgerungen und klinische Bedeutung -Die EBIC Therapie ist eine sichere und wirksame Behandlung f€ ur die cAD. Diese Therapie k€ onnte die immunologische Imbalance bei Hunden mit AD korrigieren indem man aktivierte T Lymphozyten infundiert. 要約 背景 -犬アトピー性皮膚炎(cAD)は、複数のTリンパ球とサイトカインとの間のアンバランスに関連して いる。生体外増強免疫細胞(EBIC)療法は、生体外で培養し、活性化したリンパ球を免疫機能改善目的に 患者に連続投与する方法である。 目的 -本研究の目的は、本パイロット研究は、EBIC療法の安全性を評価し、cADに対する新規治療法と してのその有効性を実証することを目的とした。 被験動物 -ADを有する10頭の犬。 方法および材料 -生体外培養前後の免疫細胞の表現型をフローサイトメトリーによって解析した。EBIC
